Benzinga
Benzinga
Benzinga
venerdì, settembre 18

Aytu BioPharma Inc

AYTUNASDAQ
Trade with Public
Trade with Public
$2.00
0.0050.25%
Ult. Agg.: Sep 18, 10:05 AM
Utili: I risultati di Q4 2026 tra 4 giorni da adesso in mar set 22nd, dopo la chiusura del mercato
Conference call: Conference call programmata per tra 4 giorni alle 4:30 PM
Clicca per vedere il webcast
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaRapporto azionario

Aytu BioPharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aytu BioPharma (AYTU).

Price Target Range — 4 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingBuy# Analysts3Avg. Consensus PT$10Upside to Avg. PT+390.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Jun 11, 2026Ascendiant CapitalEdward WooPT RaiseBuy$14→$15
Dec 10, 2025Ascendiant CapitalEdward WooPT RaiseBuy$13→$13
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $14.5

Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14 to $14.5.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $13

Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $12.5 to $13.
Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Aytu BioPharma, Lowers Price Target to $7

Maxim Group analyst Naz Rahman maintains Aytu BioPharma (NASDAQ: AYTU) with a Buy and lowers the price target from $9 to $7.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $12.5

Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ: AYTU) with a Buy and raises the price target from $12 to $12.5.
Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On Aytu BioPharma with Buy Rating, Announces Price Target of $8

Lake Street analyst Thomas Flaten initiates coverage on Aytu BioPharma (NASDAQ:AYTU) with a Buy rating and announces Price Target of $8.
Benzinga Newsdesk

This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved